Candesartan in heart failure
نویسندگان
چکیده
Candesartan cilexetil is a nonpeptide selective blocker of the angiotensin II receptor sub-type 1. It is a prodrug that is converted to its active metabolite during its variable absorption. It is highly protein bound with a small volume of distribution and a nine-hour half-life. Candesartan is one of two angiotensin receptor blockers approved for use in heart failure. MEDLINE was searched using OVID and PubMed to evaluate the evidence for using candesartan in patients with heart failure. Pharmacologic and pharmacokinetic evaluations, as well as clinical trials, were selected and are presented in this review. Clinical evidence supports the indication for use in systolic heart failure. Results for use in patients with diastolic heart failure were non-significant. Candesartan was well tolerated in the trials, with hyperkalemia, renal dysfunction, and hypotension being the most common adverse events. Use of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors needs further study; however, candesartan appears to provide added benefit in this setting. Candesartan is a safe and effective option for patients with systolic heart failure. Data regarding other angiotensin receptor blockers is underway.
منابع مشابه
Frontiers in congestive heart failure: improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil.
Background—The renin-angiotensin system plays an important part in the pathogenesis of congestive heart failure (CHF). This study evaluated the effect of an angiotensin II type 1 receptor antagonist on exercise tolerance and symptoms of CHF. Methods and Results—In this multicenter, double-blind, parallel-group study, 844 patients with CHF were randomized to 12 weeks’ treatment with placebo (n52...
متن کاملCandesartan cilexetil in the treatment of chronic heart failure
The prevalence of heart failure is ever increasing around the world, particularly due to aging populations. Despite improvements in treatment over the last 20 years, the prognosis for heart failure remains poor. Among the treatments recommended for chronic heart failure, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are crucial, provided of course that they are not contraindi...
متن کاملEffect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
BACKGROUND Patients with heart failure are at increased risk of sudden death and death attributed to progressive pump failure. We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. METHODS AND RESULTS The CHARM program consisted of 3 component trials that en...
متن کاملEffects of angiotensin II (AT1) receptor blockade on cardiac vagal control in heart failure.
The objective of the present study was to determine the autonomic effects of angiotensin II (AT(1)) receptor blocker therapy in heart failure. In a randomized double-blind cross-over study, we compared the effects of candesartan and placebo on baroreflex sensitivity and on heart rate variability at rest, during stress and during 24 h monitoring. Acute effects were assessed 4 h after oral candes...
متن کاملTreating diastolic heart failure with statins: "phat" chance for pleiotropic benefits.
Diastolic heart failure (DHF) is a significant healthcare problem.1,2 Nearly 50% of all patients with chronic heart failure have DHF. Once hospitalized for heart failure, patients with DHF have a 50% chance of rehospitalization within 6 months. Patients with DHF have a 5% to 6% yearly mortality rate. It is estimated that treating patients with DHF costs in excess of $3.5 billion/year. Despite t...
متن کامل